Kezar Life Sciences (KZR) Equity Ratio (2021 - 2025)
Kezar Life Sciences (KZR) has disclosed Equity Ratio for 5 consecutive years, with 0.91 as the latest value for Q4 2025.
- For Q4 2025, Equity Ratio rose 13.13% year-over-year to 0.91; the TTM value through Dec 2025 reached 0.91, up 13.13%, while the annual FY2025 figure was 0.91, 13.13% up from the prior year.
- Equity Ratio hit 0.91 in Q4 2025 for Kezar Life Sciences, up from 0.85 in the prior quarter.
- Across five years, Equity Ratio topped out at 0.94 in Q2 2022 and bottomed at 0.81 in Q4 2024.
- Average Equity Ratio over 5 years is 0.88, with a median of 0.89 recorded in 2023.
- Year-over-year, Equity Ratio dropped 6.77% in 2023 and then grew 13.13% in 2025.
- Kezar Life Sciences' Equity Ratio stood at 0.9 in 2021, then decreased by 0.28% to 0.9 in 2022, then dropped by 5.89% to 0.85 in 2023, then dropped by 4.69% to 0.81 in 2024, then grew by 13.13% to 0.91 in 2025.
- According to Business Quant data, Equity Ratio over the past three periods came in at 0.91, 0.85, and 0.84 for Q4 2025, Q3 2025, and Q2 2025 respectively.